Bharat Parenterals Limited Q4 FY26 Results: Loss Rs 8.16 Cr, Revenue Rs 99.62 Crore
- May 19, 2026
- Posted by: Kashish Aggarwal
- Category: News
Bharat Parenterals Limited Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Bharat Parenterals Limited reported net loss of Rs 8.16 crore for the quarter ended March 31, 2026, Q4 FY26 (results declared May 18, 2026), on revenue of Rs 99.62 crore. Bharat Parenterals Limited operates in the intravenous fluids and pharmaceutical packaging sector. Investors tracking Bharat Parenterals Limited Q4 FY26 will find complete financial analysis and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Bharat Parenterals Limited Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| Net Loss | Rs 8.16 crore | Q4 FY26 (results declared May 18, 2026) |
| Revenue from Operations | Rs 99.62 crore | Quarter ended March 31, 2026 |
| Ticker | Sector: IV Fluids |
Bharat Parenterals Limited Q4 FY26 Performance Analysis
Bharat Parenterals Limited Q4 FY26 reflects the company’s operational performance during the January to March 2026 quarter. Bharat Parenterals Limited is a leading intravenous fluids and pharmaceutical packaging company whose Q4 FY26 print sets the baseline for FY27 guidance. The reported loss reflects ongoing challenges; management guidance on FY27 recovery trajectory will be the key watchpoint. Q4 January to March is typically a seasonally strong quarter for Indian companies driven by year-end government procurement and project completion cycles.
The path to profitability in FY27 depends on volume recovery, cost reduction, and strategic business initiatives. Track Bharat Parenterals Limited on the Univest Screener for live data.
Check the Univest Screener for live data
Key Factors for the company
Revenue and Sector Dynamics
Bharat revenue of Rs 99.62 crore reflects the company’s execution in the intravenous fluids and pharmaceutical packaging space. India’s sustained economic growth of 6.5%+ and robust domestic demand across sectors provide a supportive backdrop for FY27 business planning.
Profitability and Margin Trends
The company net loss of Rs 8.16 crore Q4 FY26 (results declared May 18, 2026) demonstrates near-term margin challenges. The company’s FY27 strategy to restore profitability through volume growth and cost optimisation will be closely monitored by investors.
FY27 Business Outlook
Following the firm results, management guidance on FY27 revenue, order book, and strategic priorities will be key catalysts. Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Bharat Parenterals Limited.
Frequently Asked Questions on Bharat
What is the company PAT?
Ans. Bharat reported net loss of Rs 8.16 crore Q4 FY26 (results declared May 18, 2026). Results declared May 18, 2026. Full details from NSE/BSE regulatory filings. Verify all data before investing.
What is the company revenue?
Ans. The firm’s revenue from operations was Rs 99.62 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.
When were Bharat results announced?
Ans. The company results were announced on May 18, 2026, at the board meeting approving audited Q4 and FY26 financial statements for the year ended March 31, 2026.
Is Bharat Parenterals Limited a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, sector dynamics, and personal risk tolerance. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
